Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 11 - Commercialization and Market Assessment of COVID-19 Assays

  • Edited by Steven C. Schachter, Harvard Medical School, Wade E. Bolton, VentureWell/Rapid Acceleration of Diagnostics (RADx)
  • Book:
    Accelerating Diagnostics in a Time of Crisis
    Published online:
    06 January 2024
    Print publication:
    07 March 2024, pp 211-235

  • Summary

    Commercialization is the process of bringing diagnostics from the laboratory setting to the commercial market. Rapid Acceleration of Diagnostics (RADx®) portfolio companies were tasked with developing and producing millions of rapid, accurate, low-cost, and convenient COVID-19 tests to meet surging demand, but tests only help if people can access them. Many would-be purchasers discovered that tests alone would not solve the problem – they needed comprehensive testing solutions. In this chapter, we discuss RADx’s role in assisting portfolio companies in understanding customers’ evolving needs; the shifting market dynamics with each new wave, vaccine, or variant; and the barriers and opportunities to market success. We highlight go-to-market strategies and policy decisions that worked well and we outline policy and regulatory barriers that hindered broader success. We reflect on the lessons learned and potential solutions to adopt before the next pandemic and in the broader context of the future diagnostic delivery system.